Our patented technologies fall into five broad categories

CARvac

CARvac platform is the new generation CAR, with antigen targeting in combination with a “tumor-vaccine” effect to recruit whole body defense against disease. CARvac is designed to prevent cancer relapse due to the loss of target antigen and to overcome harsh tumor micro-environments.

Non-Gene Editing CAR Technology to treat T-cell malignancies

A major obstacle to the development of effective CAR cells targeting T-cell malignancies is the surface expression proteins overlapping that of T or NK cells used for generating CARs. The gene-edited approach requires multiple steps and are not completely understood in potential off-target effects, which are still major concerns in terms of clinical translations.

iCell adopts the non-gene editing “one-step” approach to the solution for the ongoing problems with gene editing of immune cells, specifically by preventing the offending surface molecules from being presented on the surface of the cells. iCell has first-mover technology in this area and a robust patent portfolio. The leading therapeutic in this class is our CD4 targeted CAR, which has an effective IND with US FDA. A clinical trial is being conducted by Indiana University with Stony Brook University, both programs are currently enrolling. Our patented non-gene edited CAR technology is safer, more specific and efficient methods for genetically modifying immune cells.

Read more:

Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor

Non Gene Edited Universal CARs

Long-lasting, persistent “off the shell” Natural Killer (NK) cell CAR platform (universal CAR) to expand access and reduce cost, with potential safety advantages and reduced regulatory risk over gene edited CARs. Our proprietary allogenic CAR engineered NK cells demonstrate expansion, persistency, and efficacy similar to CAR T-cells, benefits derived from proprietary technology. In Natural Killer (NK) cells there exist potential safety advantages such as no GVHD, and reduced regulatory risk.

C-TPS1

A combination platform tailored to achieve maximal antitumor efficacy by depletion of TREG, inhibition of PD-L1 immunosuppression pathway, induction of tumor vaccine effects with promotion of T or NK or innate cells and stimulation of tumor infiltrate lymphocyte proliferation, as well as enhancement of immune cells homing to the target site. Clinical trials are planning to focus on lung cancers and liver cancers.

Compound CARs

Compound chimeric antigen receptor (cCAR) engineered cellular products simultaneously express two independent, complete CAR units. This technology is superior in targeting pathologies whereby single targeting may lead to “antigen escape.” Through targeting multiple antigens independently our patented cCAR technology exerts more comprehensive killing. The cCAR constructs demonstrates increased effector cell persistency, and superior cytoxicity against heterogenous populations compared to a single expressing CAR T-cell.

Read more:

A compound chimeric antigen receptor strategy for targeting multiple myeloma

Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia